Active Pharmaceutical Ingredients (API)

PRODUCT NAMEQUALITY GRADESTATUS

Ranolazine

In-House/ USP PF 44(3)

US DMF Filed
EU ASMF Filed
China NMPA DMF Filed
 PregabalinIP/ USP/ Ph. Eur/ BP/ In-HouseUS DMF Filed
China NMPA DMF Filed
CEP Granted
JDMF Filed
KDMF Filed
ANVISA DMF Filed
Sugammadex SodiumIn-HouseEU ASMF Filed
Dolutegravir Sodium

In-House

WHO DMF Under Compilation
Levocetirizine DI-HCLUSP/IP/In-HouseValidation Completed
EmpagliflozinIn-HouseIn-House DMF Available
Ziprasidone DI-HCLUSP/IP In-House DMF Available
Doxazosin MesylateUSP/BP/In-HouseIn-House DMF Available
Alfuzosin HCLUSP/Ph.EurIn-House DMF Available
Cetirizine DI-HCLUSP/Ph.Eur/IP/BPIn-House DMF Available
Prazosin HCLUSP/EPIn-House DMF Available
 SilodosinIn-HouseIn-House DMF Available
Darunavir EthanolateIn-HouseUnder Validation
Ziprasidone Mesylate TrihydratePh.Eur/In-HouseUnder Validation
Sitagliptin Phosphate MonohydrateUSP/ Ph.Eur/ IPUnder Validation
Oclacitinib Maleate [VET]In-HouseTech Pack Ready
Azilsartan BaseIn-HouseTech Pack Ready
 Sitagliptin HCLIn-HouseTech Pack Ready
Avibactam SodiumIn-HouseUnder Development
Azilsartan MedoxomilIn-HouseUnder Development
Bempedoic AcidIn-HouseUnder Development
BilastineIn-HouseUnder Development
Candesartan CilexetilIn-HouseUnder Development
Dabigatran Etexilate MesylateIn-HouseUnder Development
FosravuconazoleIn-HouseUnder Development
GarenoxacinIn-HouseUnder Development
Pentosan Polysulfate SodiumIn-HouseUnder Development
Terazosin HCLUSPUnder Development